JRF 104
Alternative Names: JRF-104Latest Information Update: 22 Apr 2021
At a glance
- Originator Chengdu Jinrui Foundation Biotech
- Class Antineoplastics
- Mechanism of Action Axl receptor tyrosine kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia
Most Recent Events
- 22 Apr 2021 Discontinued - Preclinical for Acute myeloid leukaemia in China (PO) (Chengdu Jinrui Foundation Biotech pipeline, April 2021)
- 22 Jun 2020 Preclinical trials in Acute myeloid leukaemia in China (PO) before June 2020
- 22 Jun 2020 Pharmacodynamics data from preclinical data in Acute myeloid leukaemia presented at the 111th Annual Meeting of the American Association for Cancer Research - II (AACR-II-2020)